Tags : Cosela


G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the

Shots: On Feb 12, 2021, the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC The launch is supported by the “One Patient Support Program” which is designed to provide access and affordability solutions to eligible patients […]Read More